Moderna agrees to pay up to $2.87 billion to settle Covid-19 vaccine patent dispute

Under the deal, Moderna will pay US$950 million (S$1.21 billion) upfront in July 2026. Read more at straitstimes.com. Read more at straitstimes.com.

Moderna sued for violating patent linked to Pfizer/BioNTech COVID-19 shot

Moderna (MRNA) faces a lawsuit in the U.S. for allegedly infringing patent rights related to the COVID-19 shot developed by ...

Moderna Faces Lawsuit From BioNTech Over Next-Generation COVID-19 Shot

BioNTech SE BNTX has filed a patent infringement lawsuit against Moderna Inc. MRNA, alleging that Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, relies on proprietary technology developed and ...
Seeking Alpha

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...

How we tracked Covid updates

To help answer common vaccine questions, we consulted Dr. Stanley Perlman, a professor at the University of Iowa’s Carver College of Medicine and a member of the U.S. Food and Drug Administration’s ...
abc7NY

Pfizer and BioNTech begin application for full FDA approval of their COVID-19 vaccine

Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older, the companies said Friday. This is the ...